Scalper1 News
IBD’s Medical-Biomed/Biotech group was a big gainer in 2014, up around 41%, and the group is showing no signs of letting up. Headed into Thursday, it was the No. 1-ranked group in IBD’s database, based on six-month price performance. On Thursday, it was among the top-performing groups after AbbVie (ABBV) announced plans to buy Pharmacyclics (PCYC) for $21 billion in cash and stock. It looked like the group was ready to roll over in early February Scalper1 News
Scalper1 News